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 Introduction 
 Alzheimer’s disease (AD) is a progressive neurodegen-
erative disorder of the central nervous system that is 
characterized by impairment of memory, language and 
thought  [1] . Dementia is diagnosed when these clinical 
symptoms interfere significantly with social functioning 
and activities of daily living. At this point, considerable 
and irreversible neuronal damage has already occurred. 
Landmark neuropathological findings include selective 
neuronal and synaptic losses  [2] , extracellular neuritic 
plaques and neurofibrillary tangles. The earliest neuro-
pathological changes originate in the medial temporal 
lobe, incuding the hippocampus, the entorhinal cortex 
(EC) and the amygdala  [3–5] . There is an increasing in-
terest in the identification of patients in the earliest stage 
of AD, prior to clinical manifestation of dementia, in or-
der to provide effective early intervention that aims at 
delaying significant impairment  [6, 7] .
 It has been shown consistently that mild cognitive im-
pairment (MCI) is a predementia syndrome  [8] . MCI is 
defined as objective cognitive decline with intact activi-
ties of daily living  [9] . Several studies have demonstrated 
that MCI patients are at higher risk of developing AD, 
with an estimated conversion rate of 10–15% per year, 
compared to 1–2% per year in the cognitively healthy el-
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 Abstract 
 Background/Aims: Subjective memory impairment (SMI) 
has been suggested as a manifestation of Alzheimer’s Dis-
ease (AD) preceding mild cognitive impairment (MCI). In this 
study, we determined the volumes of the hippocampus, the 
entorhinal cortex (EC) and the amygdala to provide biologi-
cal evidence for AD in SMI.  Methods: Regional volumetric 
measures were manually traced on 3-Tesla MRI scans.  Re-
sults: Total brain volume did not differ between the groups. 
Individuals with SMI had reduced volumes of the hippocam-
pus bilaterally (right p = 0.001; left p  ! 0.001), the bilateral EC 
(right p = 0.031, left p = 0.006) and the right amygdala (p = 
0.01) compared to the control group.  Conclusion: Volume 
reduction of bilateral hippocampus, bilateral EC and right 
amygdala supports the concept of SMI as a very early mani-
festation of AD prior to MCI. SMI may indicate awareness of 
a degenerative process that can still be functionally com-
pensated.  Copyright © 2010 S. Karger AG, Basel 
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derly  [8, 10] . In patients with MCI, neuropathology stud-
ies have reproducibly detected neuronal loss in medial 
temporal lobe structures, including the hippocampus, 
EC and amygdala  [11, 12] . Consistent with these findings, 
several structural brain MRI studies reported smaller 
volumes of the hippocampus, the EC and the amygdala 
in patients with MCI compared with unimpaired elderly 
 [13–15] . It has been suggested that atrophy of medial tem-
poral lobe structures predict progression from MCI to 
AD  [16, 17] .
 Neuropathological features of AD, however, are pres-
ent even years prior to clinical manifestation of MCI  [18] . 
Since cognitive impairment develops slowly, it has been 
suggested that subjective memory impairment (SMI) 
may precede MCI in the clinical manifestation of AD  [19, 
20] . SMI is defined by the mere subjective feeling of mem-
ory decline, but – in contrast to MCI – persons with SMI 
perform within the normal range on standard neuropsy-
chological tests. The concept of SMI as a precursor of AD 
is supported by the majority of longitudinal studies in 
large cohorts that identified SMI as a predictor of demen-
tia  [21, 22] .
 In a pilot MRI study, we found a reduction of the EC 
volume in SMI subjects as compared with controls who 
did not complain of impairment, providing evidence of 
AD-related neurodegeneration  [22] . Total hippocampal 
volume was not reduced in that sample; however, 3-di-
mensional surface analysis revealed a localized volume 
reduction  [23] . Other studies with limited sample size 
also failed to identify hippocampal volume reduction in 
SMI  [24] . In larger SMI samples, however, hippocampal 
volume reduction was observed  [25, 26] . The aim of the 
present study was threefold: (1) to identify hippocampal 
volume reduction in a larger and independent SMI sam-
ple as compared with our initial study  [27] ; (2) to replicate 
the finding of EC volume reduction in SMI, and (3) to ad-
ditionally measure the volume of the amygdala, as a me-
dial temporal lobe structure that is vulnerable to early 
AD pathology.
 Subjects and Methods 
 Subjects 
 All participants with SMI (n = 21) were referrals to the mem-
ory clinic of the Department of Psychiatry of the University of 
Bonn for the diagnostic work-up of memory complaints. We only 
included subjects with informant confirmation of memory de-
cline. The consensus of self and informant responses increases the 
validity of reports of memory impairment  [28] . The onset of 
memory impairment had to have been observed within the last 10 
years in all subjects. The time criterion was employed to exclude 
subjects with lifelong memory complaints.
 The healthy control subjects (n = 48) without memory com-
plaints were recruited from the general population by advertise-
ment. None reported any significant memory decline or impair-
ment.
 The 2 groups did not differ with regard to age, gender or years 
of education ( table 1 ).
 Normal cognitive function in all participants was defined by 
the CERAD (Consortium to Establish a Registry for Alzheimer’s 
Disease) neuropsychological battery  [29] for which German age-, 
gender- and education-adjusted norms are available at www.
memoryclinic.ch. All subjects with SMI and all healthy controls 
scored within 1.5 SD on all subtests of the CERAD battery. The 
SMI group did not differ from the healthy control group on any 
CERAD item ( table 2 ). There was, however, a significant differ-
ence in the Mini-Mental State Examination (MMSE) between 
both groups.
 All participants underwent the Structured Clinical Interview 
for DSM-IV to identify current or lifetime psychiatric diagnoses. 
Subjects with any psychiatric disorder at present or in the past 
were excluded. Only a single depressive episode more than 10 
years ago, which was reported by 2 subjects with SMI and 4 sub-
jects in the control group, was not considered an exclusion crite-
ria. Current (sub-threshold) depressive symptoms were addition-
ally evaluated by the Beck’s Depression Inventory (BDI). This self-
rating scale contains 21 questions, each answer is scored on a scale 
value of 0 to 3. A total score greater than 12 indicates a clinically 
relevant depression.
 Additional exclusion criteria for both groups were any signif-
icant past or present neurological or medical diseases. Patients 
with medication that is known to affect brain function were not 
included.
 Apolipoprotein E (ApoE) genotype was determined in all sub-
jects. The groups did not differ with regard to the presence of the 
ApoE 4 allele ( table 1 ).
 All participants gave written informed consent prior to their 
inclusion in the study. The local ethical committee approved all 
procedures used in this study.
Table 1. Sample description
SMI
(n = 21)
Controls
(n = 48)
Difference
Age, years 66.386.15 65.887.22 T = 0.29
p = 0.774
Male/female 15/6 31/17 2 = 0.308
p = 0.579
Years of education 14.683.57 15.182.8 T = –0.65
p = 0.515
BDI 6.284.8 2.7582.8 T = 3.77
p < 0.001*
ApoE (4+/4–) 5/16 11/37 2 = –0.001,
p = 0.971
* Significant differences compared with the control group.
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 Magnetic Resonance Imaging 
 All magnetic resonance (MR) data were obtained on a 3T MR 
scanner (Philips Achieva, Philips, Best, The Netherlands), 
equipped with an 8-channel sense head coil. Four high-resolution 
T 1 -weighted data sets of each participant were acquired consecu-
tively. The sequence parameters were as follows: T 1 -weighted 3D 
Turbo Field Echo (FFE), sense factor 2.5 in the AP direction, 1.5 
in the RL direction, TE/TR/Flip = 3.6 msec/7.6 msec/8°, field of 
view 256  ! 256 mm, matrix size 320  ! 320, number of slices 170, 
spatial resolution 0.8  ! 0.8  ! 0.8 mm. The loss in signal-to-noise 
ratio due to the high resolution and the application of sensitivity 
encoding was compensated by acquiring 4 independent data sets 
which were averaged post hoc after applying a motion correction 
algorithm as provided by SPM5 (Wellcome Department of Cogni-
tive Neurology, London).
 MR Analyses 
 All volumetric measures were performed by 1 blinded rater 
(A.W.). The software Analyze 5.0 was used. Prior to the measure-
ment of the target regions, the rater performed a blinded double 
measure of all regions in 10 subjects. These data were used to cal-
culate the intra-rater variability by means of Pearson correlation 
coefficient. The total brain volumes were obtained by automated 
tissue segmentation with SPM5 and adding of grey and white 
matter tissue probability maps.
 Volumetric Measures 
 Hippocampus 
 The right and left hippocampi were manually traced on sagittal 
MR slices, starting on a midsagittal slice throughout the hippo-
campus. The anterior border was defined by the alveus, which sep-
arates the hippocampus from the amygdala. The lateral ventricle 
served as the posterior border. The fimbria as well as the lateral 
ventricle and the alveus defined the superior border. Inferiorly the 
uncus separated the hippocampus from the parahippocampal gy-
rus. On further medial slices the hippocampus is divided into 2 
separate structures by thalamic nuclei. The head of the hippocam-
pus borders the temporal horn of the lateral ventricle from ventral, 
while the tail borders the same structure dorsally. The intra-rater 
reliability of the hippocampal volume was r = 0.98.
 Entorhinal Cortex 
 The EC protocol was adapted from Insausti et al.  [30] and 
Goncharova et al.  [31] . The EC was measured from the level where 
the ambiens gyrus, the amygdala and the white matter of the 
parahippocampal gyrus were first visible to the section preceding 
the lateral geniculate nucleus. The superior boundary was defined 
as the sulcus semiannularis and, in more caudal sections, the in-
ferior border of the subiculum. The lateral border was defined as 
the most inferior medial point of the medial bank of the collat-
eral sulcus. The intra-rater reliability of the EC volume according 
to this protocol was r = 0.97.
 Amygdala 
 The volumes of the amygdalae were defined according to 
Pruessner et al.  [32] . They were manually traced on coronal slices. 
The posterior end of the amygdala was defined as the point where 
grey matter first appeared superior to the alveus, lateral of the hip-
pocampus. A horizontal line between the superolateral part of the 
optic tract and the fundus of the inferior portion of the circular 
sulcus of the insula was employed as superior border. Defining the 
tentorial indentation as the inferior border allowed a separation 
between amygdala and EC. Anteriorly, the border was set by the 
closure of the lateral sulcus. To define the medial and lateral bor-
ders of the amygdala, transverse slices were used. The medial pos-
terior-superior ambient cistern was separated from the amygdala, 
while further anterior and inferior it had to be distinguished from 
the EC. Laterally the inferior horn of the lateral ventricle marked 
the border. The intra-rater reliability of the protocol was r = 
0.98.
 Statistics 
 The data were analyzed with SPSS for Windows (v. 16.0 in Ger-
man). To correct for overall brain atrophy, all volumes were di-
vided by whole brain volume.
 Univariate analyses of variance (ANOVA) were used to assess 
group differences of any volumetric measure for each hemisphere 
separately and for the combined left and right volumes. Sex and 
ApoE 4 status (carrier/non-carrier) were included as factors. Age, 
BDI and MMSE were introduced as covariates. Additionally, the 
interaction of age and amygdala volume was also calculated. Ef-
fect sizes d were calculated for each group comparison according 
to: 
	 
 	 

	 
 	 
2 2 /2
Control SMI
Control SMI
mean X mean X
d
std X std X


SMI
(n = 21)
Controls
(n = 48)
Difference
T p
Mini-mental state examination 28.681.2 29.381.0 –2.64 0.01
Semantic verbal fluency (1 min) 24.185.5 25.785.9 –1.08 0.282
Boston naming test (max. 15) 14.880.6 14.780.5 0.38 0.71
Verbal immediate recall (max. 30) 22.283.3 22.883.3 –0.66 0.52
Verbal delayed recall (max. 10) 7.981.6 8.081.5 –0.25 0.68
Verbal recognition (max. 10) 9.880.4 9.880.6 0.41 0.344
Constructional practice (max. 11) 10.481.0 10.780.7 –1.53 0.13
Visual recall 10.183.1 11.282.0 1.72 0.09
Table 2. Neuropsychological test scores 
derived from the CERAD neuropsycho-
logical battery
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 Results 
 Brain volume did not differ between both groups. The 
SMI group had smaller bilateral hippocampi and EC as 
compared with the control subjects. The right amygdala 
was also smaller in the SMI group as compared with the 
controls. The left amygdala volume did not differ be-
tween both groups.  Table 3 lists the data of all regions. Of 
all covariates in all analyses, only age was significantly 
associated with amygdala volume in the whole sample 
[left amygdala F = 9.382, p = 0.003; right amygdala F = 
7.678, p = 0.008; summed (right + left) amygdala F = 
10.195, p = 0.002]. There was no association between 
amygdala volume and age in the SMI subsample. There 
was an association between the right, left and summed 
amygdala volume in the control subsample (left amyg-
dala r = –0.406, p = 0.004; right amygdala r =
–0.445, p = 0.002; summed amygdala r = 0.462, p = 
0.001).
 Discussion 
 We found volume reduction of bilateral hippocampus, 
the bilateral EC and the right amygdala in subjects with 
SMI in comparison to control subjects. The 2 groups did 
not differ with regard to cognitive performance. Vari-
ables impacting on brain volumes, such as age, BDI, 
MMSE, sex and ApoE4 status, were included as covari-
ates. In a pilot study with an independent smaller sample, 
we did not observe significant volume reduction of the 
hippocampus in SMI subjects as compared with controls 
 [27] . One potential reason for this inconsistency is the 
difference in sample size between the 2 studies. Another 
explanation could be that the pilot study was performed 
on a 1.5-T scanner, while in the current study all MR data 
were obtained on a 3-T MR scanner with a resolution of 
0.8  ! 0.8  ! 0.8 mm as opposed to 1  ! 1 ! 1 mm, po-
tentially yielding a higher sensitivity. Another reason 
could be that in the pilot study SMI was defined as self-
reported feeling of memory worsening with normal neu-
ropsychological performance. In the present study we ad-
ditionally included only subjects with informant confir-
mation of memory decline. The consensus of self and 
informant responses increases the validity of reports of 
memory impairment  [28] . The significant reduction of 
the hippocampus in the present study confirms other re-
ports of hippocampal volume reduction in SMI  [25, 26] . 
Hippocampal atrophy has been shown to be one of the 
most robust and consistently documented findings in 
mild AD and MCI and can be detected very early in the 
disease process  [33] . At present, there is increasing evi-
dence that hippocampal atrophy can be observed prior to 
the MCI stage in AD with SMI as the corresponding clin-
ical syndrome. In a large population-based sample Stew-
art et al.  [34] found an association between lower hippo-
campal volume and subjective memory impairment. But 
the authors only discriminated between dementia, SMI 
and non-complaining persons. Individuals with mild 
neuropsychological deficits might have been included in 
the SMI group. In our study we only included persons 
that performed within the normal range on standard 
neuropsychological tests.
Table 3. Volumetric measures normalized to total brain volume
Controls SMI dF F p Effect size
Total brain volume 1.0280.09 1.0180.12 1 0.980 0.756 –0.09
Summed hippocampus (right + left) 4.0380.55 3.5580.39 1 14.909 <0.001* –1.01
Left hippocampus 2.0480.30 1.8080.20 1 15.769 0.000* –0.94
Right hippocampus 2.0080.27 1.7580.22 1 11.314 0.001* –1.02
Summed EC (right + left) 1.0380.25 0.7880.19 1 7.304 0.009* –1.13
Left EC 0.5180.13 0.3780.09 1 8.316 0.006* –1.25
Right EC 0.5180.14 0.4280.12 1 4.913 0.031* –0.69
Summed amygdala (right + left) 2.7780.38 2.5180.40 1 5.088 0.028* –0.67
Left amygdala 1.3980.21 1.2980.19 1 2.119 0.151 –0.50
Right amygdala 1.3880.20 1.2280.23 1 7.162 0.010* –0.74
* Significant differences compared with the control group (ANOVA using age, BDI and MMSE as covariates, 
and sex and presence of ApoE4 as factors). 
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 We replicated our initial finding of EC volume loss in 
SMI in an independent sample of SMI subjects and con-
trols  [27] . In keeping with the literature, EC atrophy has 
repeatedly been demonstrated in patients with pre-de-
mentia syndromes  [35] . Similar to our data, Dickerson et 
al.  [16] reported a significant volume reduction of the EC 
and hippocampus in individuals who reported memory 
decline. The group of memory complainers, however, in-
cluded both, patients with SMI and MCI. The authors did 
not differentiate between these 2 subgroups. Killiany et al. 
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 Fig. 1. Left and right volumes of the entorhinal cortex, amygdala, hippocampus normalized to total brain volume. 
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 [33] reported that EC atrophy predicts dementia within 3 
years and found that the EC is affected earlier than the 
hippocampus. In our study the effect size of the summed 
EC volume reduction was slightly greater than the effect 
size of the summed hippocampal volume reduction, which 
may indicate more pronounced volume reduction con-
firming neuropathological models.
 As a novel finding we also observed volume reduction 
of the right amgdala in SMI subjects. The amygdala is less 
frequently the target of volumetric studies in AD and 
MCI. However, those studies that assessed amygdala vol-
ume, consistently found a reduction in patients with AD 
compared with healthy elderly individuals  [36, 37] . In 
subjects with MCI, Bottino et al.  [38] reported smaller 
amygdala volumes in comparison with healthy elderly 
subjects. Accordingly, Petersen et al.  [39] found that most 
patients with MCI met neuropathological criteria for in-
cipient AD up to Braak III stage, including amygdala af-
fection. In a population-based cohort, den Heijer et al. 
 [40] reported prediction of dementia by amygdala and 
hippocampal atrophy in cognitively healthy subjects  [40] . 
Respectively, Stewart et al.  [34] found an association be-
tween amygdala atrophy and persons with SMI in their 
large community sample.
 A correlation between amygdala atrophy and aging 
has consistently been reported. In our study amygdala 
volume was only negatively associated with age in the 
control subsample, but not in the SMI subsample. This 
may be interpreted as an indication of an accelerated 
amygdala volume reduction in the SMI group obscuring 
normal effects of aging.
 With regard to degree of atrophy expressed by effect 
size, the affection of the EC and the hippocampus is 
greater that that of the amygdala in our study. This fits 
the proposed pathological staging scheme in AD. Ac-
cording to the Braak stages neurofibrillary tangels first 
occur in the EC and hippocampus (transentorhinal stag-
es I and II), before spreading out into the amygdala and 
basolateral temporal lobe (limbic stage III–IV)  [3] .
 We found differences in atrophy between the left and 
right hemisphere. While the volume of the right amyg-
dala was smaller in the SMI group compared with the 
control subjects, the left amygdala was not. By contrast, 
the effect size of the right EC difference between both 
groups was smaller than that of the left EC difference. 
Thus, we did not observe clear laterality effects. This 
might be attributable to the sample size. However, the lit-
erature regarding laterality of volume atrophy in MCI 
and AD is very heterogeneous without clear evidence of 
either left of right dominance of atrophy  [38] .
 Our study has limitations. First, this is a cross-section-
al investigation. Only longitudinal follow-up will eventu-
ally confirm the hypothesis of brain volume atrophy as 
an indicator of AD in SMI. However, observation periods 
of many years are needed to identify reliably who will 
eventually suffer from dementia  [19, 20] .
 A potential confound is the slightly higher score on the 
depression self-rating scale (BDI) in the SMI group. How-
ever, neither the SMI subjects nor the healthy controls 
had a clinically relevant depression or fulfilled DSM IV 
criteria for a major depressive episode. Still, we accounted 
for this potential confound by including the BDI score as 
a covariate in all analyses. We did not find an association 
of any measure with the BDI score. Also, higher BDI 
score in the SMI group may not necessarily reflect sub-
threshold depressive symptoms, but may be related to dif-
ferences in self-awareness due to specific personality 
traits, which have been found to be more prevalent in SMI 
subjects  [41] . In this study, we did not assess these vari-
ables in detail.
 Another limitation in terms of the generalizibility is 
the memory clinic based origin of our sample, with most 
participants having high levels of education and superior 
pre-morbid cognitive performance, which may modulate 
effects of brain pathology on cognition  [35] . However, our 
data are in agreement with findings from population-
based studies  [26] .
 Finally, SMI as a category is not yet fully established 
and there is no standard definition. Also, mediotemporal 
lobe atrophy is not specific for early AD as it occurs also 
in other neurodegenerative disorders. This has to be con-
sidered when comparing these data with other studies.
 In conclusion, in SMI subjects we observed structural 
brain changes that are similar to those seen in MCI and 
mild AD. We replicated hippocampus and EC volume re-
duction and extended these findings to reduction of the 
right amygdala volume. These results further support the 
model of SMI as an early clinical correlate of AD pathol-
ogy. Subjective cognitive failures may indicate the aware-
ness of very mild early impairment that is still compen-
sated.
 Acknowledgments 
 The study was supported by the Alzheimer Forschungsinitia-
tive (AFI) and the German Dementia Competence Network 
(DCN) funded by the German Federal Ministry for Education 
and Research (grant O1GI 0102). 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
1/
20
16
 3
:5
4:
20
 P
M
 Volume Loss of Medial Temporal Lobe in 
Subjective Memory Impairment 
Dement Geriatr Cogn Disord 2010;29:75–81 81
 References 
 1 Cummings JL, Cole G: Alzheimer disease. J 
Am Med Assoc 2002; 287: 2335–2338. 
 2 Morris JH, Hof PR: Life and death of neurons 
in the aging brain. Science 1997; 78: 412–419. 
 3 Braak H, Braak E: Neuropathological stag-
ing of Alzheimer-related changes. Acta Neu-
ropathol (Berl) 1991; 82: 239–259. 
 4 Frisoni GB, Beltramello A, Weiss C, et al: 
Linear measures of atrophy in mild Alzhei-
mer disease. Am J Neuroradiol 1996; 17: 913–
923. 
 5 Laakso MP, Soininen H, Partanen K, et al: 
Volumes of hippocampus, amygdala and 
frontal lobes in the MRI-based diagnosis of 
early Alzheimer’s disease: correlation with 
memory functions. J Neural Transm Park 
Dis Dement 1995; 9: 73–86. 
 6 Gauthier S, Poerier J: Current and future 
management of Alzheimer’s disease. Alz-
heimer Dementia 2008; 4:S48–S50. 
 7 Fillit H: Drug discovery and the prevention 
of Alzheimer’s disease. Alzheimers Dement 
2008; 4:S26–S28. 
 8 Petersen RC, Doody R, Kurz A, et al: Current 
concepts in mild cognitive impairment. 
Arch Neurol 2001; 58: 1985–1992. 
 9 Winblad B, Palmer K, Kivipelto M, et al: 
Mild cognitive impairment-beyond contro-
versies towards a consensus: report of the In-
ternational Working Group on Mild Cogni-
tive Impairment. J Intern Med 2004; 256: 
 240–246. 
 10 Petersen RC: Mild cognitive impairment as a 
diagnostic entity. J Intern Med 2004; 256: 
 183–184. 
 11 Barnes LL, Schneider JA, Boyle PA, Bienias 
JL, Bennett DA: Memory complaints are re-
lated to Alzheimer disease pathology in old-
er persons. Neurology 2006; 67: 1581–1585. 
 12 Morris JC, Price AL: Pathologic correlates of 
nondemented aging, mild cognitive impair-
ment, and early-stage Alzheimer’s disese. J 
Mol Neurosci 2001; 17: 101–118. 
 13 Hua X, Leow AD, Parikshak N, et al: Tensor-
based morphometry as a neuroimaging bio-
marker for Alzheimer’s disease: an MRI 
study of 676 AD, MCI and normal subjects. 
Neuroimage 2008; 43: 458–469. 
 14 Seo SW, Im K, Lee JM, et al: Cortical thick-
ness in single-versus multiple-domain am-
nestic mild cognitive impairment. Neuroim-
age 2007; 36: 289–297. 
 15 Whitwell JL; Shiung MM, Przybelski SA, et 
al: MRI patterns of atrophy associated with 
progression to AD in amnestic mild cogni-
tive impairment. Neurology 2008; 70: 512–
520. 
 16 Dickerson BC, Goncharova I, Sullican MP, et 
al: MRI-derived entorhinal and hippocam-
pal atrophy in incipient and very mild Alz-
heimer’s disease. Neurobiol Aging 2001; 22: 
 747–754. 
 17 Visser PJ, Verhey FR, Hofman PA, et al: Me-
dial temporal lobe atrophy predicts Alz-
heimer’s disease in patients with minor cog-
nitive impairment. J Neurol Neurosurg 
Psychiatry 2002; 72: 491–497. 
 18 Delacourte A, David JP, Sergeant N, et al: 
The biochemical pathway of neurofibrillary 
degeneration in aging and Alzheimer’s dis-
ease. Neurology 1999; 52: 1158–1165. 
 19 Gauthier S, Juby A, Morelli L, et al: A large, 
naturalistic, community-based study of 
 rivastigmine in mild-to-moderate AD: the 
EXTEND study. Curr Med Res Opin 2006; 
 22: 2251–2265. 
 20 Reisberg B, Gauthier S: Current evidence for 
subjective cognitive impairment (SCI) as the 
pre-mild cognitive impairment (MCI) stage 
of subsequently manifest Alzheimer’s dis-
ease. Int Psychogeriatr 2008; 20: 1–16. 
 21 Jonker C, Geerlings MI, Schmand B: Are 
memory complaints predictive for demen-
tia? A review of clinical and population-
based studies. Int J Geriatr Psychiatry 2000; 
 15: 983–991. 
 22 Jessen F, Wiese B, Bachmann C, et al: Predic-
tion of dementia by subjective memory im-
pairment-effects of severity and temporal as-
sociation with cognitive impairment. Arch 
Gen Psychiatry 2009, in press. 
 23 Tepest R, Wang L, Csernansky JG, et al: Hip-
pocampal surface analysis in subjective 
memory impairment, mild cognitive im-
pairment and Alzheimer’s dementia. De-
ment Geriatr Cogn Disord 2008; 26: 323–
329. 
 24 Chao S, Robert JS, Mareau TM, et al: Health 
behaviour changes after genetic risk assess-
ment for Alzheimer disease: the REVEAL 
Study. Alzheimer Dis Assoc Disord 2008; 22: 
 94–97. 
 25 Saykin AJ, Wishart HA, Rabin LA, et al: Old-
er adults with cognitive complaints show 
brain atrophy similar to that of amnestic 
MCI. Neurology 2006; 67: 834–842. 
 26 Van Norden AG, Fick WF, de Laat KF, et al: 
Subjective cognitive failures and hippocam-
pal volume in elderly with white matter le-
sions. Neurology 2008; 71: 1152–1159.  
 27 Jessen F, Feyen L, Freymann K, et al: Volume 
reduction of the entorhinal cortex in subjec-
tive memory impairment. Neurobiol Aging 
2006; 27: 1751–1756. 
 28 Carr DB, Gray S, Baty J, Morris JC: The value 
of informant versus individual’s complaints 
of memory impairment in early dementia. 
Neurology 2000; 55: 1724–1726. 
 29 Morris JC, Heyman A, Mohs RC, et al: The 
Consortium to Establish a Registry for Alz-
heimer’s Disease (CERAD). Part I. Clinical 
and neuropsychological assessment of Alz-
heimer’s disease. Neurology 1989; 39: 1159–
1165. 
 30 Insausti R, Juottonen K, Soininen H, et al: 
MR volumetric analysis of the human ento-
rhinal, perirhinal, and temporopolar corti-
ces. AJNR 1998; 19: 659–671. 
 31 Goncharova Il, Dickerson BC, Stoub TR, et 
al: MRI of human entorhinal cortex: a reli-
able protocol for volumetric measurement. 
Neurobiol Aging 2001; 22: 737–745. 
 32 Pruessner JC, Li LM, Series W, et al: Volum-
etry of hippocampus and amygdala with 
high-resolution MRI and three-dimensional 
analysis software: minimizing the discrep-
ancies between laboratories. Cereb Cortex 
2000; 10: 433–442. 
 33 Killiany RJ, Gomez-Isla T, Moss M, et al: Use 
of structural magnetic resonance imaging to 
predict who will get Alzheimer’s disease. 
Ann Neurol 2000; 47: 420–439. 
 34 Stewart MD, Dufouil C, Godin O, et al: Neu-
roimaging correlates of subjective memory 
deficits in a community population. Neurol-
ogy 2008; 70: 1601–1607. 
 35 Rentz DM, Huh TJ, Faust RR, et al: Use of 
IQ-adjusted norms to predict progressive 
cognitive decline in highly intelligent older 
individuals. Neuropsychology 2004; 18: 38–
49. 
 36 Horinek D, Varjassyova A, Hort J: Magnetic 
resonance analysis of amygdalar volume in 
Alzheimer’s disease. Curr Opin Psychiatry 
2007; 20: 272–277. 
 37 Teipel SJ, Pruessner JC, Faltraco F, et al: 
Comprehensive dissection of the medial 
temporal lobe in AD: measurement of hip-
pocampus, amygdala, entorhinal, perirhinal 
and parahippocampal coritces using MRI. J 
Neurol 2006; 253: 794–800. 
 38 Bottino CM, Castro CC, Gomes RL, et al: 
Volumetric MRI measurements can differ-
entiate Alzheimer’s disease, mild cognitive 
impairment, and normal aging. Int Psycho-
geriatr 2002; 14: 59–72. 
 39 Petersen RC, Parisi JE, Dickson DW, et al: 
Neuropathologic features of amnestic mild 
cognitive impairment. Arch Neurol 2006; 63: 
 665–672. 
 40 den Heijer T, Geerlings MI, Hoebeek FE, et 
al: Use of hippocampal and amygdalar vol-
umes on magnetic resonance imaging to pre-
dict dementia in cognitively intact lederly 
people. Arch Gen Psychiatry 2006; 63: 5–62. 
 41 Jungwirth S, Fischer P, Weissgram S, et al: 
Subjective memory complaints and objective 
memory impairment in the Vienna-Trans-
danube aging community. J Am Geriatr Soc 
2004; 52: 263–268. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
1/
20
16
 3
:5
4:
20
 P
M
